MedTrace Logo

Assessment of SOLO Vibrating Mesh Nebulizer for Allergen-Induced Late Asthmatic Responses

NCT04630405 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2020-11-16

No results posted yet for this study

Summary

This is a mechanistic study. Having established safety with the Solo® nebulizer and the ability to predict allergen PD20 using the methacholine PD20 and STE, the current study will assess the use of the Solo® vibrating mesh nebulizer on development of allergen-induced endpoints during the late phase response.

Conditions

Interventions

DEVICE

Wright jet nebulizer

Roxon Medi-Tech, Montreal, QC, Canada

DEVICE

Aerogen Solo

Aerogen Ltd., Galway, Ireland

Sponsors & Collaborators

Principal Investigators

  • Gail Gauvreau, PhD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630405 on ClinicalTrials.gov